Publicações científicas

What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Bronte G(1), Rolfo C(2), Passiglia F(1), Rizzo S(1), Gil-Bazo I(3), Fiorentino E(4), Cajozzo M(5), Van Meerbeeck JP(6), Lequaglie C(7), Santini D(8), Pauwels P(9), Russo A(1).

(1) Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
(2) Phase I-Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.
(3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Department of Surgical, Oncological and Oral Sciences, Section of Surgical Oncology, University of Palermo, Palermo, Italy.
(5) Department of Surgical, Oncological and Oral Sciences, Section of Thoracic Surgery, University of Palermo, Palermo, Italy.
(6) Thoracic Oncology, Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.
(7) Department of Thoracic Surgery, I.R.C.C.S.-C.R.O.B. Basilicata Regional Cancer Institute, Rionero in Vulture, Italy.
(8) Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
(9) Molecular Pathology Unit, Pathology Department and Multidisciplinary Oncology Center Antwerp (MOCA) Antwerp University Hospital, Edegem, Belgium.

Revisão:Critical Reviews in Oncology/Hematology

Data: 11/Abr/2015

Oncologia Médica

BACKGROUND:
Randomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.

MATERIALS AND METHODS:
Data from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3-4 (G3-4) hematologic toxicities.

RESULTS:
Six eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883-5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203-2.525) in favor of platinum-based doublets. G3-4 hematological toxicities were also more frequent in this group.

CONCLUSION:
This meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.

CITAÇÃO DO ARTIGO  Crit Rev Oncol Hematol. 2015 Apr 11. pii: S1040-8428(15)00066-9. doi: 10.1016/j.critrevonc.2015.03.010.

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra